Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0

Antoine Verger; Nelleke Tolboom; Francesco Cicone; Susan M. Chang; Julia Furtner; Norbert Galldiks; Jens Gempt; Eric Guedj; Raymond Y. Huang; Derek R. Johnson; Ian Law; Emilie Le Rhun; Susan C. Short; M. J.Van den Bent; Donatienne Van Weehaeghe; Michael A. Vogelbaum; Patrick Y. Wen; Nathalie L. Albert; Matthias Preusser

doi:10.1007/s00259-024-07038-5

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0

Antoine Verger^*, Nelleke Tolboom, Francesco Cicone, Susan M. Chang, Julia Furtner, Norbert Galldiks, Jens Gempt, Eric Guedj, Raymond Y. Huang, Derek R. Johnson, Ian Law, Emilie Le Rhun, Susan C. Short, M. J.Van den Bent, Donatienne Van Weehaeghe, Michael A. Vogelbaum, Patrick Y. Wen, Nathalie L. Albert, Matthias Preusser

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [¹⁸F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.

Original language	English
Pages (from-to)	1822-1839
Number of pages	18
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	52
Issue number	5
Early online date	7 Jan 2025
DOIs	https://doi.org/10.1007/s00259-024-07038-5
Publication status	Published - Apr 2025

Keywords

Brain metastases
Brain metastasis
FDG
FDOPA
FET
Fluciclovine
Metastatic brain tumors
Methionine
PET
Recurrence

Access to Document

10.1007/s00259-024-07038-5Licence: CC BY

s00259-024-07038-5Final published version, 1.08 MBLicence: CC BY

Cite this

Verger, A., Tolboom, N., Cicone, F., Chang, S. M., Furtner, J., Galldiks, N., Gempt, J., Guedj, E., Huang, R. Y., Johnson, D. R., Law, I., Le Rhun, E., Short, S. C., Bent, M. J. V. D., Weehaeghe, D. V., Vogelbaum, M. A., Wen, P. Y., Albert, N. L., & Preusser, M. (2025). Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 52(5), 1822-1839. https://doi.org/10.1007/s00259-024-07038-5

@article{a3ba723e71b1403f9ff00a0c274ef500,

title = "Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0",

abstract = "This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [18F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.",

keywords = "Brain metastases, Brain metastasis, FDG, FDOPA, FET, Fluciclovine, Metastatic brain tumors, Methionine, PET, Recurrence",

author = "Antoine Verger and Nelleke Tolboom and Francesco Cicone and Chang, {Susan M.} and Julia Furtner and Norbert Galldiks and Jens Gempt and Eric Guedj and Huang, {Raymond Y.} and Johnson, {Derek R.} and Ian Law and {Le Rhun}, Emilie and Short, {Susan C.} and Bent, {M. J.Van den} and Weehaeghe, {Donatienne Van} and Vogelbaum, {Michael A.} and Wen, {Patrick Y.} and Albert, {Nathalie L.} and Matthias Preusser",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = apr,

doi = "10.1007/s00259-024-07038-5",

language = "English",

volume = "52",

pages = "1822--1839",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer-Verlag",

number = "5",

}

Verger, A, Tolboom, N, Cicone, F, Chang, SM, Furtner, J, Galldiks, N, Gempt, J, Guedj, E, Huang, RY, Johnson, DR, Law, I, Le Rhun, E, Short, SC, Bent, MJVD, Weehaeghe, DV, Vogelbaum, MA, Wen, PY, Albert, NL & Preusser, M 2025, 'Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0', European Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 5, pp. 1822-1839. https://doi.org/10.1007/s00259-024-07038-5

TY - JOUR

T1 - Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases

T2 - version 1.0

AU - Verger, Antoine

AU - Tolboom, Nelleke

AU - Cicone, Francesco

AU - Chang, Susan M.

AU - Furtner, Julia

AU - Galldiks, Norbert

AU - Gempt, Jens

AU - Guedj, Eric

AU - Huang, Raymond Y.

AU - Johnson, Derek R.

AU - Law, Ian

AU - Le Rhun, Emilie

AU - Short, Susan C.

AU - Bent, M. J.Van den

AU - Weehaeghe, Donatienne Van

AU - Vogelbaum, Michael A.

AU - Wen, Patrick Y.

AU - Albert, Nathalie L.

AU - Preusser, Matthias

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2025/4

Y1 - 2025/4

N2 - This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [18F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.

AB - This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [18F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.

KW - Brain metastases

KW - Brain metastasis

KW - FDG

KW - FDOPA

KW - FET

KW - Fluciclovine

KW - Metastatic brain tumors

KW - Methionine

KW - PET

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85214404464&partnerID=8YFLogxK

U2 - 10.1007/s00259-024-07038-5

DO - 10.1007/s00259-024-07038-5

M3 - Article

C2 - 39762634

AN - SCOPUS:85214404464

SN - 1619-7070

VL - 52

SP - 1822

EP - 1839

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 5

ER -

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this